Evidence map›Paper›PMID 36438884›Full record

ReviewWorld journal of gastrointestinal endoscopy2022

Current approaches and questions yet to be resolved for the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Hirokazu Saito, Atsushi Fujimoto, Kana Oomoto, Yoshitaka Kadowaki, Shuji Tada

Open access · diamondAbstract readReview
In one paragraph

Review in World journal of gastrointestinal endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hirokazu SaitoDepartment of Gastroenterology, Kumamoto City Hospital, Kumamoto City 862-8505, Kumamoto, Japan. arnestwest@yahoo.co.jp.
Atsushi FujimotoDepartment of Gastroenterology, Kumamoto City Hospital, Kumamoto City 862-8505, Kumamoto, Japan.
Kana OomotoDepartment of Gastroenterology, Kumamoto City Hospital, Kumamoto City 862-8505, Kumamoto, Japan.
Yoshitaka KadowakiDepartment of Gastroenterology, Kumamoto City Hospital, Kumamoto City 862-8505, Kumamoto, Japan.
Shuji TadaDepartment of Gastroenterology, Kumamoto City Hospital, Kumamoto City 862-8505, Kumamoto, Japan.
Kumamoto City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prophylaxis is important for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), which is the most common and serious complication of ERCP. Although the current guidelines include independent patient- and procedure-related risk factors for PEP and available PEP prophylactic measures, the synergistic effect of these risk factors on PEP should also be considered, given that patients often harbor multiple risk factors. Furthermore, a combination of prophylactic measures is often selected in clinical practice. However, established methods estimating the synergistic effect of independent risk factors on PEP incidence are lacking, and evidence on the impact of combining prophylactic measures on PEP should be discussed. Selection of appropriate candidate patients for ERCP is also important to reduce the incidence of PEP associated with unnecessary ERCP. ERCP indications in patients with asymptomatic common bile duct stones (CBDSs) and in those with suspected CBDSs with no imaging-based evidence of stones are controversial. Further studies are warranted to predict the synergistic effect of independent risk factors on PEP, determine the best prophylactic PEP measures, and identify appropriate candidates for ERCP in patients with asymptomatic CBDSs and those with suspected CBDSs.

Indexed as

Endoscopic retrograde cholangiopancreatographyGuidelinesPost-endoscopic retrograde cholangiopancreatography pancreatitisProphylaxis

Identifiers

PMID36438884
PMCPMC9693687
OpenAlexW4309044131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.